# US 2024/0175866 A1 · Method for Detecting Coronavirus Infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0175866 A1
- Document ID: US20240175866A1
- Status: Published application
- Kind: A1
- Application number: 18/281,094
- Filed: 2022-03-09
- Published: 2024-05-30
- Earliest claimed: 2021-03-10
- Assignees: National University Corporation Kumamoto University; Shimadzu Corporation; AiSTI SCIENCE CO., Ltd.
- Applicants: National University Corporation Kumamoto University; Shimadzu Corporation; AiSTI SCIENCE Co., Ltd.
- Inventors: Kazuhito TOMIZAWA; Yu NAGAYOSHI
- Web page: https://patentgrep.com/patent/US20240175866A1

## CPC

- G01N 33/5308: {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites}
- C12Q 1/34: involving hydrolase
- G01N 27/62: by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode
- G01N 33/50: Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing (measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q)
- G01N 33/53: Immunoassay; Biospecific binding assay; Materials therefor
- G01N 2800/50: Determining the risk of developing a disease
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

An object of the present invention is to provide a method for determining that a subject is at risk of suffering or is suffering from COVID-19. The present invention provides a method for determining whether a subject that is a mammal is at risk of suffering or suffering from COVID-19, the method including a step of detecting the amount of at least one modified nucleoside selected from the group consisting of 6-threonylcarbamoyl adenosine (t6A) and 2-thiomethyl,6-threonylcarbamoyl adenosine (ms2t6A) in a sample derived from the subject.

## Claims

### Claim 1

A method for determining a treatment policy of a subject that is a mammal based on a result of determining whether the subject is at risk of suffering or is suffering from COVID-19, the method comprising:
a step of detecting an amount of a modified nucleoside which is 6-threonylcarbamoyl adenosine (t6A) and/or 2-thiomethyl,6-threonylcarbamoyl adenosine (ms2t6A) in a sample derived from the subject;
a step of determining whether the subject is at risk of suffering or is suffering from COVID-19 based on the amount of the modified nucleoside detected; and
a step of determining a treatment policy of the subject based on a result of the determination.

### Claim 2 (depends on 1)

The method according to claim 1, further comprising a step of determining whether the subject is at risk of suffering or is suffering from COVID-19 by comparing the amount of the modified nucleoside detected with a predetermined reference value.

### Claim 3 (depends on 1)

The method according to claim 1, further comprising a step of evaluating severity (degree of COVID-19 morbidity) of a subject based on the amount of the modified nucleoside detected.

### Claim 4 (depends on 2)

The method according to claim 2, further comprising a step of predicting a subsequent change in pathology of the subject based on the amount of the modified nucleoside detected.

### Claim 5

A method for determining a treatment policy of a subject that is a mammal suffering from COVID-19, the method comprising:
a step of detecting an amount of a modified nucleoside which is 6-threonylcarbamoyl adenosine (t6A) and/or 2-thiomethyl,6-threonylcarbamoyl adenosine (ms2t6A) in a sample derived from a subject;
a step of evaluating a therapeutic effect in the subject based on the amount of the modified nucleoside detected; and
a step of determining a treatment policy of the subject based on a result of the evaluation.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the sample is plasma, serum, or urine.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the amount of the modified nucleoside is detected by tandem mass spectrometry (MS/MS).

### Claim 8 (depends on 7)

The method according to claim 7, wherein the sample is a sample subjected to deproteinization and desalination.

### Claim 9 (depends on 7)

The method according to claim 7, wherein the sample is plasma or serum, and the step of detecting the amount of the modified nucleoside includes a step of correcting a measurement result with an amount of adenosine in the plasma or the serum.

### Claim 10 (depends on 7)

The method according to claim 7, wherein the sample is urine, and the step of detecting the amount of the modified nucleoside includes a step of correcting a measurement result with an amount of at least one substance selected from the group consisting of creatinine, urea nitrogen, uric acid, adenosine, and 3-amino-3-carboxypropyl uridine in the urine.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the amount of the modified nucleoside is detected by an ELISA method.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the subject is a human.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the subject is a febrile patient.

### Claim 14

A method for determining a treatment policy of a subject that is a mammal based on a result of determining whether the subject is a therapeutic subject of COVID-19, the method comprising:
a step of detecting an amount of a modified nucleoside which is 6-threonylcarbamoyl adenosine (t6A) and/or 2-thiomethyl,6-threonylcarbamoyl adenosine (ms2t6A) in a sample derived from the subject;
a step of determining whether the subject is a therapeutic subject of COVID-19 based on the amount of the modified nucleoside detected; and
a step of determining a treatment policy of the subject based on a result of the determination.

### Claim 15

A method for determining a treatment policy of a subject that is a mammal suffering from COVID-19, the method comprising:
a step of detecting an amount of a severity marker or severity predictive marker of COVID-19, made of 6-threonylcarbamoyl adenosine (t6A) and/or 2-thiomethyl,6-threonylcarbamoyl adenosine (ms2t6A), in a sample derived from a subject;
a step of determining severity of the subject based on the amount of the severity marker or severity predictive marker detected; and
a step of determining a treatment policy of the subject based on a result of the determination.

### Claim 16 (depends on 5)

The method according to claim 5, wherein the sample is plasma, serum, or urine.

### Claim 17 (depends on 15)

The method according to claim 15, wherein the sample is plasma, serum, or urine.

### Claim 18 (depends on 5)

The method according to claim 5, wherein the amount of the modified nucleoside is detected by tandem mass spectrometry (MS/MS).

### Claim 19 (depends on 15)

The method according to claim 15, wherein the amount of the modified nucleoside is detected by tandem mass spectrometry (MS/MS).
